Thrombin-induced platelet aggregation −effect of dabigatran using automated platelet aggregometry−

References

• Coughlin SR. Thrombin signaling and protease-activated receptors. Nature 2000;407:258–264. doi:10.1038/35025229
   PubMed Web of Science ®Google Scholar
• Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 1999;103:879–887. doi:10.1172/JCI6042
   PubMed Web of Science ®Google Scholar
• Jeong YH, Kim IS, Choi BR, Kwak CH, Hwang JY. The optimal threshold of high post-treatment platelet reactivity could be defined by a point-of-care VerifyNow P2Y12 assay. Eur Heart J 2008;29:2186–2187. doi:10.1093/eurheartj/ehn313
   PubMed Web of Science ®Google Scholar
• Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, et al., GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011;305:1097–1105. doi:10.1001/jama.2011.290
   PubMed Web of Science ®Google Scholar
• Linnemann B, Schwonberg J, Rechner AR, Mani H, Lindhoff-Last E. Assessment of clopidogrel non-response by the PFA-100 system using the new test cartridge Innovance PFA P2Y. Ann Hematol 2010;89:597–605. doi:10.1007/s00277-009-0881-9
   PubMed Web of Science ®Google Scholar
• Linnemann B, Schwonberg J, Mani H, Prochnow S, Lindhoff-Last E. Standardization of light transmittance aggregometry for monitoring antiplatelet therapy: an adjustment for platelet count is not necessary. J Thromb Haemost 2008;6:677–683. doi:10.1111/j.1538-7836.2008.02891.x
   PubMed Web of Science ®Google Scholar
• Lawrie AS, Kobayashi K, Lane PJ, Mackie IJ, Machin SJ. The automation of routine light transmission platelet aggregation. Lab Hem 2014;36:431–438. doi:10.1111/ijlh.12161
   PubMed Web of Science ®Google Scholar
• Ling LQ, Liao J, Niu Q, Wang X, Jia J, Zuo CH, Jiang H, Zhou J. Evaluation of an automated light transmission aggregometry. Platelets 2017;28:712–719. doi:10.1080/09537104.2016.1265923
   PubMed Web of Science ®Google Scholar
• Platton S, McCormick Á, Bukht M, Gurney D, Holding I, Moore GW. A multicenter study to evaluate automated platelet aggregometry on Sysmex CS-series coagulation analyzers-preliminary findings. Res Pract Thromb Haemost 2018;30:778–789. doi:10.1002/rth2.12140
   Google Scholar
• Canobbio I, Cipolla L, Consonni A, Momi S, Guidetti G, Oliviero B, Falasca M, Okigaki M, Balduini C, Gresele P, et al. Impaired thrombin-induced platelet activation and thrombus formation in mice lacking the Ca(2+)-dependent tyrosine kinase Pyk2. Blood 2013;121:648–657. doi:10.1182/blood-2012-06-438762
   PubMed Web of Science ®Google Scholar
• French SL, Paramitha AC, Moon MJ, Dickins RA, Hamilton JR. Humanizing the Protease-Activated Receptor (PAR) expression profile in mouse platelets by knocking PAR1 into the Par3 locus reveals PAR1 expression is not tolerated in mouse platelets. PLoS One 2016;11:e0165565. doi:10.1371/journal.pone.0165565
   PubMed Web of Science ®Google Scholar
• Vinholt PJ, Nielsen C, Söderström AC, Brandes A, Nybo M. Dabigatran reduces thrombin-induced platelet aggregation and activation in a dose-dependent manner. J Thromb Thrombolysis 2017;44:216–222. doi:10.1007/s11239-017-1512-2
   PubMed Web of Science ®Google Scholar
• Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 2007;98:155–162.
   PubMed Web of Science ®Google Scholar
• Vu T-KH, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991;64:1057–1068.
   PubMed Web of Science ®Google Scholar
• Xu WF, Andersen H, Whitmore TE, Presnell SR, Yee DP, Ching A, Gilbert T, Davie EW, Foster DC. Cloning and characterization of human protease-activated receptor 4. Proc Natl Acad Sci USA 1998;95:6642–6646. doi:10.1073/pnas.95.12.6642
   PubMed Web of Science ®Google Scholar
• Michelson AD. Platelet activation by thrombin can be directly measured in whole blood through the use of the peptide GPRP and flow cytometry: methods and clinical applications. Blood Coagul Fibrinolysis 1994;5:121–131.
   PubMed Web of Science ®Google Scholar
• Achyuthan KE, Dobson JV, Greenberg CS. Gly-Pro-Arg-Pro modifies the glutamine residues in the alpha- and gamma-chains of fibrinogen: inhibition of transglutaminase cross-linking. Biochim Biophys Acta 1986;872:261–268.
   PubMedGoogle Scholar
• Kogushi M, Matsuoka T, Kawata T, Kuramochi H, Kawaguchi S, Murakami K, Hiyoshi H, Suzuki S, Kawahara T, Kajiwara A, et al. The novel and orally active thrombin receptor antagonist E5555 (Atopaxar) inhibits arterial thrombosis without affecting bleeding time in guinea pigs. Eur J Pharmacol 2011;657:131–137. doi:10.1016/j.ejphar.2011.01.058
   PubMed Web of Science ®Google Scholar
• Michelson AD. Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov 2010;9:154–169. doi:10.1038/nrd2957
   PubMed Web of Science ®Google Scholar
• Gremmel T, Michelson AD, Frelinger AL III, Bhatt DL. Novel aspects of antiplatelet therapy in cardiovascular disease. Res Pract Thromb Haemost 2018;2:439–449. doi:10.1002/rth2.12115
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, et al., RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139–1151. doi:10.1056/NEJMoa0905561
   PubMed Web of Science ®Google Scholar
• Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, Ezekowitz MD, Nehmiz G, Wang S, Wallentin L, RE-LY Investigators. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 2014;63:321–328. doi:10.1016/j.jacc.2013.07.104
   PubMed Web of Science ®Google Scholar
• Hartter S, Sennewald R, Schepers C, Baumann S, Fritsch H, Friedman J. Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers. Eur J Clin Pharmacol 2013;69:327–339. doi:10.1007/s00228-012-1304-8
   PubMed Web of Science ®Google Scholar
• Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008;36:386–399. doi:10.1124/dmd.107.019083
   PubMed Web of Science ®Google Scholar
• Stangier J, Rathgen K, Stahle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010;49:259–268. doi:10.2165/11318170-000000000-00000
   PubMed Web of Science ®Google Scholar
• Terayama Y. Evaluation of the efficacy and safety of direct oral anticoagulants in Japanese patients-analysis of pharmaceuticals and medical devices agency data. J Stroke Cerebrovasc Dis 2017;26:1171–1181. doi:10.1016/j.jstrokecerebrovasdis.2016.12.035
   PubMed Web of Science ®Google Scholar
• Uesugi T, Baba Y, Kohara S, Shimizu M, Mizuma A, Yutani S, Ohnuki Y, Nagata E, Takizawa S. Clinical utility of platelet function testing following non-cardioembolic stroke, Tokai J Exp Clin Med 2015;20:178–184.
   Google Scholar
• Cattaneo M, Lecchi A, Zighetti ML, Lussana F. Platelet aggregation studies: autologous platelet-poor plasma inhibits platelet aggregation when added to platelet-rich plasma to normalize platelet count. Haematologica 2007;92:694–697.
   PubMed Web of Science ®Google Scholar
• Singh VP, Singh MK, Kumar V, Sinha MK, Dwivedi RC, Rai M, Dube B. Antithrombin III activity in cerebrovascular accidents. J Assoc Physicians India 2003;51:268–271.
   PubMedGoogle Scholar
• Cucuianu MP, Cristea A, Roman S, Missits I. Increased plasma antithrombin III level in hyperlipidemic subjects. Clin Chim Acta 1981;110:147–155.
   PubMed Web of Science ®Google Scholar
• Carvalho A, Ellman L. Hereditary antithrombin III deficiency. Effect of antithrombin III deficiency on platelet function. Am J Med 1976;61:179–183.
   PubMed Web of Science ®Google Scholar
• Hawes EM, Deal AM, Funk-Adcock D, Gosselin R, Jeanneret C, Cook AM, Taylor JM, Whinna HC, Winkler AM, Moll S. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost 2013;11:1493–1502. doi:10.1111/jth.12308
   PubMed Web of Science ®Google Scholar